Fierce Pharma Asia—Roche, GSK, Novartis billion-dollar deals; More MFN sign-ups; Akeso’s OS win

GSK, Roche and Novartis continued their dealmaking spree with Asian companies. Three midsized Asian biopharmas reached MFN deals with the White House. Akeso and Summit's ivonescimab delivered a head-to-head overall survival win against Keytruda. And more.